Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph A Jakubowski

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
Biomarkers in Medicine|February 16, 2011
Beyond platelet functional testing: value in the aggregateJoseph A Jakubowski
Seminars in Thrombosis and Hemostasis|April 27, 2005
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activityYoichi Niitsu, Joseph A Jakubowski, Atsuhiro Sugidachi, et al.
Cardiovascular Drug Reviews|December 15, 2007
Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profileJoseph A Jakubowski, Kenneth J Winters, Hideo Naganuma, et al.
Thrombosis Research|October 23, 2015
Prevention of occlusive arterial thrombus formation by a single loading dose of prasugrel suppresses neointimal hyperplasia in miceKousaku Ohno, Atsuyuki Tomizawa, Joseph A Jakubowski, et al.
European Journal of Pharmacology|June 19, 2016
The active metabolite of prasugrel, R-138727, improves cerebral blood flow and reduces cerebral infarction and neurologic deficits in a non-human primate model of acute ischaemic strokeAtsuhiro Sugidachi, Makoto Mizuno, Kousaku Ohno, et al.
Thrombosis Research|March 18, 2015
Characterization of platelet aggregation responses in microminipigs: Comparison with miniature pigs and the influence of dual antiplatelet administration of aspirin plus prasugrelKousaku Ohno, Atsuyuki Tomizawa, Joseph A Jakubowski, et al.
Plos One|April 30, 2016
A Novel Model of Intravital Platelet Imaging Using CD41-ZsGreen1 Transgenic RatsMakoto Mizuno, Atsuyuki Tomizawa, Kousaku Ohno, et al.
Thrombosis and Haemostasis|August 2, 2013
Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregationAtsuyuki Tomizawa, Kousaku Ohno, Joseph A Jakubowski, et al.
Thrombosis Research|September 22, 2015
Prasugrel reduces ischaemic infarct volume and ameliorates neurological deficits in a non-human primate model of middle cerebral artery thrombosisAtsuyuki Tomizawa, Kousaku Ohno, Joseph A Jakubowski, et al.
Journal of the American Heart Association|April 8, 2016
Prasugrel, a Platelet P2Y12 Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb IschemiaKousaku Ohno, Atsuyuki Tomizawa, Makoto Mizuno, et al.
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
Biomarkers in Medicine|February 16, 2011
Beyond platelet functional testing: value in the aggregateJoseph A Jakubowski
Seminars in Thrombosis and Hemostasis|April 27, 2005
Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activityYoichi Niitsu, Joseph A Jakubowski, Atsuhiro Sugidachi, et al.
Cardiovascular Drug Reviews|December 15, 2007
Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profileJoseph A Jakubowski, Kenneth J Winters, Hideo Naganuma, et al.
Thrombosis Research|October 23, 2015
Prevention of occlusive arterial thrombus formation by a single loading dose of prasugrel suppresses neointimal hyperplasia in miceKousaku Ohno, Atsuyuki Tomizawa, Joseph A Jakubowski, et al.
European Journal of Pharmacology|June 19, 2016
The active metabolite of prasugrel, R-138727, improves cerebral blood flow and reduces cerebral infarction and neurologic deficits in a non-human primate model of acute ischaemic strokeAtsuhiro Sugidachi, Makoto Mizuno, Kousaku Ohno, et al.
Thrombosis Research|March 18, 2015
Characterization of platelet aggregation responses in microminipigs: Comparison with miniature pigs and the influence of dual antiplatelet administration of aspirin plus prasugrelKousaku Ohno, Atsuyuki Tomizawa, Joseph A Jakubowski, et al.
Plos One|April 30, 2016
A Novel Model of Intravital Platelet Imaging Using CD41-ZsGreen1 Transgenic RatsMakoto Mizuno, Atsuyuki Tomizawa, Kousaku Ohno, et al.
Thrombosis and Haemostasis|August 2, 2013
Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregationAtsuyuki Tomizawa, Kousaku Ohno, Joseph A Jakubowski, et al.
Thrombosis Research|September 22, 2015
Prasugrel reduces ischaemic infarct volume and ameliorates neurological deficits in a non-human primate model of middle cerebral artery thrombosisAtsuyuki Tomizawa, Kousaku Ohno, Joseph A Jakubowski, et al.
Journal of the American Heart Association|April 8, 2016
Prasugrel, a Platelet P2Y12 Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb IschemiaKousaku Ohno, Atsuyuki Tomizawa, Makoto Mizuno, et al.
Pageof 12